Special Issue

Nano-Drug Delivery Systems: Tackling Cancer Metabolism and Drug Resistance

Message from the Guest Editor

Cancer remains a leading cause of mortality worldwide, with therapeutic resistance and metabolic plasticity posing major challenges to effective treatment. This Special Issue focuses on the development and application of nano-drug delivery systems designed to target cancer metabolism and overcome drug resistance mechanisms. Nanotechnology offers unique advantages, such as targeted delivery, improved bioavailability, and controlled release, that can enhance the efficacy of anticancer agents while minimizing systemic toxicity. Of particular interest are nanosystems that disrupt metabolic pathways like glycolysis, glutaminolysis, and oxidative phosphorylation, or that modulate the tumor microenvironment to sensitize resistant cancer cells to therapy. We invite original research articles, reviews, and short communications that explore innovative nanocarriers, combination strategies, and preclinical or clinical advances in this field. By integrating nanotechnology with a deep understanding of tumor biology, this Special Issue aims to pave the way for next-generation therapies that effectively combat cancer progression and treatment resistance.

Guest Editor

Dr. Odília Queirós

UNIPRO—Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences, CESPU, CRL, 4585-116 Gandra, Portugal

Deadline for manuscript submissions

31 December 2025



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/245141

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

